Substitution monotherapy and add-on therapy were equally effective as a second-line treatment for women with idiopathic generalized epilepsy, with no significant differences in failure rates between ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. today announced that the company has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the ...
Hosted on MSN
Scientists map brain network linked to generalized seizures, paving way for new brain stimulation therapies
Generalized epilepsy has traditionally been considered a seizure of the "'whole brain.'" However, new research has challenged this longstanding idea, since carefully targeting specific brain areas ...
NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic ...
NASHVILLE, Tennessee ―The retention rate for the antiseizure drug perampanel (Eisai Co, Ltd) is more than 70% for adult patients with epilepsy, new research shows. In early results from the PERPRISE ...
-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...
You can expect most epilepsy cases to improve with antiseizure drugs. Surgery is an option if medications do not work for your epilepsy. You may eat a ketogenic diet to help with treatment-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results